PLA2R1 and metabolic syndrome: However, we believe that more focus should be targeted on dyslipidemia’s impact on TE-risk in patients with MN and anti-PLA2R antibodies, and if such patients would benefit from lipid-lowering therapy even if other risk factors for MN-associated thrombogenesis are absent.